This is a working overview of Heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-15 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues; tuftsin plus a Pro-Gly-Pro tail |
| Molecular formula | C33H57N11O9 | Commonly reported value for the free peptide |
| Monoisotopic mass | Roughly 751.4 Da | Average molecular mass near 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Freely soluble in water | Also dissolves in saline and other polar solvents |
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Britain withdrew most of its High Commission staff from Salisbury in the days following UDI, leaving a small skeleton staff to man a "residual mission" intended to help Gibbs keep the British government informed of local happenings. Several countries followed Britain's lead and closed their consulates in Salisbury, with one prominent exception to this being the United States, which retained its consulate-general in post-UDI Rhodesia, relabelling it a "US Contacts Office" to circumvent the problem of diplomatic recognition. South Africa and Portugal maintained "Accredited Diplomatic Representative" offices in Salisbury, which were embassies in all but name, while Rhodesia kept its pre-UDI overseas missions in Pretoria, Lisbon and Lourenço Marques. Unofficial representative offices of the Rhodesian government also existed in the US, Japan and West Germany, while a citizen of Belgium was employed to represent Rhodesian interests there with the Rhodesia Information Centre being in Australia to represent Rhodesia. The Rhodesian High Commission in London, located at Rhodesia House on the Strand, remained under the control of the post-UDI government and effectively became its representative office in the UK. Like the South African Embassy on Trafalgar Square, Rhodesia House became a regular target for political demonstrations. These continued even after Britain forced the office to close in 1969.
== Function == In the lymphatic system, a lymph node is a secondary lymphoid organ. The primary function of lymph nodes is the filtering of lymph to identify and fight infection. In order to do this, lymph nodes contain lymphocytes, a type of white blood cell, which includes B cells and T cells. These circulate through the bloodstream and enter and reside in lymph nodes. B cells produce antibodies. Each antibody has a single predetermined target, an antigen, that it can bind to. These circulate throughout the bloodstream and if they find this target, the antibodies bind to it and stimulate an immune response. Each B cell produces different antibodies, and this process is driven in lymph nodes. B cells enter the bloodstream as "naive" cells produced in bone marrow. After entering a lymph node, they then enter a lymphoid follicle, where they multiply and divide, each producing a different antibody. If a cell is stimulated, it will go on to produce more antibodies (a plasma cell) or act as a memory cell to help the body fight future infection. If a cell is not stimulated, it will undergo apoptosis and die. Antigens are molecules found on bacterial cell walls, chemical substances secreted from bacteria, or sometimes even molecules present in body tissue itself. These are taken up by cells throughout the body called antigen-presenting cells, such as dendritic cells. These antigen presenting cells enter the lymph system and then lymph nodes. They present the antigen to T cells and, if there is a T cell with the appropriate T cell receptor, it will be activated.
Diphenhydramine, while traditionally known as an antagonist, acts primarily as an inverse agonist of the histamine H1 receptor. It is a member of the ethanolamine class of antihistaminergic agents. By reversing the effects of histamine on the capillaries, it can reduce the intensity of allergic symptoms. It also crosses the blood–brain barrier and inversely agonizes the H1 receptors centrally. Its effects on central H1 receptors cause drowsiness. Diphenhydramine is a potent antimuscarinic (a competitive antagonist of muscarinic acetylcholine receptors) and, as such, at high doses can cause anticholinergic syndrome. The utility of diphenhydramine as an antiparkinson agent is the result of its blocking properties on the muscarinic acetylcholine receptors in the brain. Diphenhydramine also acts as an intracellular sodium channel blocker, which is responsible for its actions as a local anesthetic. Diphenhydramine has also been shown to inhibit the reuptake of serotonin. It has been shown to be a potentiator of analgesia induced by morphine, but not by endogenous opioids, in rats. The drug has also been found to act as an inhibitor of histamine N-methyltransferase (HNMT).
== October == Air Force Magazine published the story "The forgotten Americans of the Vietnam War" about U.S. POWs. The story was read into the Congressional Record and republished in the November issue of Reader's Digest raising the profile of U.S. POWs and MIAs.
Sources: en.wikipedia.org
== See also == Lists of investigational drugs List of investigational anxiety disorder drugs List of investigational social anxiety disorder drugs List of investigational panic disorder drugs List of investigational post-traumatic stress disorder drugs
== Cross-Linked Enzyme Aggregates (CLEAs) == The use of cross-linked enzyme crystals (CLECs) as industrial biocatalysts was pioneered by Altus Biologics in the 1990s. CLECs proved to be significantly more stable to denaturation by heat, organic solvents and proteolysis than the corresponding soluble enzyme or lyophilized (freeze-dried) powder. CLECs are robust, highly active immobilized enzymes of controllable particle size, varying from 1 to 100 micrometer. Their operational stability and ease of recycling, coupled with their high catalyst and volumetric productivities, renders them ideally suited for industrial biotransformations. However, CLECs have an inherent disadvantage: enzyme crystallization is a laborious procedure requiring enzyme of high purity, which translates to prohibitively high costs. The more recently developed cross-linked enzyme aggregates (CLEAs), on the other hand, are produced by simple precipitation of the enzyme from aqueous solution, as physical aggregates of protein molecules, by the addition of salts, or water miscible organic solvents or non-ionic polymers. The physical aggregates are held together by covalent bonding without perturbation of their tertiary structure, that is without denaturation. Subsequent cross-linking of these physical aggregates renders them permanently insoluble while maintaining their pre-organized superstructure, and, hence their catalytic activity. This discovery led to the development of a new family of immobilized enzymes: cross-linked enzyme aggregates (CLEAs).
Gender care in the Netherlands is insured under the national health care of third part insurer's, including laser hair removal, SRS, facial feminization surgery and hormones. Hormones can be prescribed by licensed endocrinologist in an academic hospital from the age 16 and older. Blockers can be prescribed from age 12 when puberty usually starts. The Dutch Ministry of Health, Welfare and Sport publishes guidelines recommending the use of puberty blockers in transgender adolescents of at least Tanner Stage II with informed consent and approval of an endocrinologist. This guideline, published in 2016, is endorsed by the following Dutch medical organizations:
=== Treatment === Pentosan polysulfate (PPS) may slow the progression of the disease, and may have contributed to the longer than expected survival of the seven people studied. The CJD Therapy Advisory Group to the UK Health Departments advises that data are not sufficient to support claims that pentosan polysulfate is an effective treatment and suggests that further research in animal models is appropriate. A 2007 review of the treatment of 26 people with PPS finds no proof of efficacy because of the lack of accepted objective criteria, but it was unclear to the authors whether that was caused by PPS itself. In 2012 it was claimed that the lack of significant benefits has likely been caused because of the drug being administered very late in the disease in many patients. Use of RNA interference to slow the progression of scrapie has been studied in mice. The RNA blocks the production of the protein that the CJD process transforms into prions. Both amphotericin B and doxorubicin have been investigated as treatments for CJD, but as yet there is no strong evidence that either drug is effective in stopping the disease. Further study has been conducted with other medical drugs, but none are effective. However, anticonvulsants and anxiolytic agents, such as valproate or a benzodiazepine, may be administered to relieve associated symptoms. Quinacrine, a medicine originally created for malaria, has been evaluated as a treatment for CJD.
== Hadamard transform time-of-flight mass spectrometry == Hadamard transform time-of flight mass spectrometry (HT-TOFMS) is a mode of mass analysis used to significantly increase the signal-to-noise ratio of a conventional TOFMS. Whereas traditional TOFMS analyzes one packet of ions at a time, waiting for the ions to reach the detector before introducing another ion packet, HT-TOFMS can simultaneously analyze several ion packets traveling in the flight tube. The ions packets are encoded by rapidly modulating the transmission of the ion beam, so that lighter (and thus faster) ions from all initially released packets of mass from a beam get ahead of heavier (and thus slower) ions. This process creates an overlap of many time-of-flight distributions convoluted in form of signals. The Hadamard transform algorithm is then used to carry out the deconvolution process which helps to produce a faster mass spectral storage rate than traditional TOFMS and other comparable mass separation instruments.
Sources: en.wikipedia.org
The short-duration response is related to the half-life of the drug. The longer-duration response depends on the accumulation of effects over at least two weeks, during which ΔFosB accumulates in nigrostriatal neurons. In the treatment of Parkinson's disease, this response stays stable up to 10 years.
Copernicium has no stable or naturally occurring isotopes. Several radioactive isotopes have been synthesized in the laboratory, either by fusing two atoms or by observing the decay of heavier elements. Eight different isotopes have been reported with mass numbers 277 and 280–286, and one unconfirmed metastable isomer in 285Cn has been reported. Most of these decay predominantly through alpha decay, but some undergo spontaneous fission, and copernicium-283 may have an electron capture branch. The isotope copernicium-283 was instrumental in the confirmation of the discoveries of the elements flerovium and livermorium.
Stable nuclei, and unstable nuclei with very long half-lives, follow a trend of stability evident when Z is plotted against N. For lighter nuclei less than N = 20, the line has the slope N = Z, while the heavier nuclei require additional neutrons to remain stable. Nuclei that are neutron- or proton-rich have excessive binding energy for stability, and the excess energy may convert a neutron to a proton or a proton to a neutron via the weak nuclear force, a process known as beta decay. Neutron-induced fission of U-235 emits a total energy of 207 MeV, of which about 200 MeV is recoverable, Prompt fission fragments amount to 168 MeV, which are easily stopped with a fraction of a millimeter. Prompt neutrons total 5 MeV, and this energy is recovered as heat via scattering in the reactor. However, many fission fragments are neutron-rich and decay via β− emissions. According to Lilley, "The radioactive decay energy from the fission chains is the second release of energy due to fission. It is much less than the prompt energy, but it is a significant amount and is why reactors must continue to be cooled after they have been shut down and why the waste products must be handled with great care and stored safely."
2C-B tablets often contain a dose of 5 or 10 mg of the drug. Low doses of 2C-B like 5 to 10 mg orally are said to produce stimulation, entactogen-like effects, and perceptual enhancement, while higher doses like 10 to 20 mg orally are said to produce psychedelic and hallucinogenic effects. 2C-B is frequently used at low doses as a substitute for MDMA. It is often used by people who go to electronic music festivals, also known as raves. The drug is also frequently used at clubs and parties, at home, or in nature. 2C-B is often combined with other drugs, such as MDMA, alcohol, and cannabis. Besides recreational use, 2C-B has been used in psychedelic-assisted psychotherapy at doses of 15 to 30 mg orally.
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.
No peptide with this exact sequence has been identified as an endogenous substance. It is a laboratory-designed analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The Pro-Gly-Pro extension has no known natural source.
Proline introduces conformational constraints that make a peptide less accessible to common peptidases. This is a standard stabilization strategy in peptide design. The added residues also increase the distance between the active tuftsin portion and typical cleavage sites.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.